Matches in Wikidata for { <http://www.wikidata.org/entity/Q67132953> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q67132953 description "clinical trial" @default.
- Q67132953 description "ensayu clínicu" @default.
- Q67132953 description "klinisch onderzoek" @default.
- Q67132953 description "клінічне випробування" @default.
- Q67132953 name "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)" @default.
- Q67132953 name "Efficacy and Safety Study of Certolizumab Pegol" @default.
- Q67132953 type Item @default.
- Q67132953 label "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)" @default.
- Q67132953 label "Efficacy and Safety Study of Certolizumab Pegol" @default.
- Q67132953 prefLabel "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)" @default.
- Q67132953 prefLabel "Efficacy and Safety Study of Certolizumab Pegol" @default.
- Q67132953 P1050 Q67132953-7148E422-D7A9-41F4-A5E0-20CAF0D695B2 @default.
- Q67132953 P1132 Q67132953-8AE1EB9D-EA75-4546-89FA-ACB0D6F5331D @default.
- Q67132953 P1476 Q67132953-475202B6-4C81-4FBC-822A-1655168C16DB @default.
- Q67132953 P17 Q67132953-1761E7DF-EFFF-4ACC-A7FD-2D4A099C19EC @default.
- Q67132953 P17 Q67132953-3E3BFE53-510F-4956-ADA5-1A01A1040AEE @default.
- Q67132953 P17 Q67132953-3EDF1109-E297-4A51-921F-77B8EBEE24B7 @default.
- Q67132953 P17 Q67132953-893290EF-9A07-449A-88D8-3F55D4F5D091 @default.
- Q67132953 P17 Q67132953-90250D42-0B94-402C-A620-7739C4F088F8 @default.
- Q67132953 P17 Q67132953-B06272BB-F4E3-48A9-83F8-E9FA621FCB82 @default.
- Q67132953 P17 Q67132953-B29BD541-6BDF-4849-A288-5E5A932F8346 @default.
- Q67132953 P17 Q67132953-BDD8ECCB-DA5E-45F6-93F5-D119CD5E1115 @default.
- Q67132953 P1813 Q67132953-E11EACBC-91A0-4107-9212-5736C557F39D @default.
- Q67132953 P2899 Q67132953-0341467C-B6D7-47F6-AE1E-2A0016D44A32 @default.
- Q67132953 P3098 Q67132953-5FA39755-2179-41FF-8167-2D9D06830011 @default.
- Q67132953 P31 Q67132953-6AA92E8F-1E7E-40E4-9DB5-9C6AC84B9C6F @default.
- Q67132953 P4844 Q67132953-20AEB503-D0F1-4889-BA5A-6355D29C5C2F @default.
- Q67132953 P580 Q67132953-906B8994-1B48-4744-B7B5-2EFA6E9818EC @default.
- Q67132953 P582 Q67132953-64AF1EB5-B4E1-4A59-98EC-82590C11627C @default.
- Q67132953 P6099 Q67132953-E7A4D92A-B9CA-41B9-9D7E-3B0555B6D20F @default.
- Q67132953 P8363 Q67132953-4206D418-1459-4CC3-836D-F9472A75C843 @default.
- Q67132953 P1050 Q179945 @default.
- Q67132953 P1132 "+559" @default.
- Q67132953 P1476 "A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q67132953 P17 Q142 @default.
- Q67132953 P17 Q145 @default.
- Q67132953 P17 Q183 @default.
- Q67132953 P17 Q219 @default.
- Q67132953 P17 Q28 @default.
- Q67132953 P17 Q30 @default.
- Q67132953 P17 Q36 @default.
- Q67132953 P17 Q55 @default.
- Q67132953 P1813 "CIMPACT" @default.
- Q67132953 P2899 "+18" @default.
- Q67132953 P3098 "NCT02346240" @default.
- Q67132953 P31 Q30612 @default.
- Q67132953 P4844 Q412909 @default.
- Q67132953 P580 "2015-02-11T00:00:00Z" @default.
- Q67132953 P582 "2016-03-22T00:00:00Z" @default.
- Q67132953 P6099 Q42824827 @default.
- Q67132953 P8363 Q78089383 @default.